A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  De Vos, Sven ^a   Forero Torres, Andres ^b   Ansell, Stephen M ^c   Kahl, Brad ^d   Cheson, Bruce D ^e   Bartlett, Nancy L ^f   Furman, Richard R ^g   Winter, Jane N ^h   Kaplan, Henry ⁱ   Timmerman, John ^a   Whiting, Nancy C ^j   Drachman, Jonathan G ^j   Advani, Ranjana ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ SWEDISH MEDICAL CENTER   (United States)

^j SEATTLE GENETICS INC   (United States)

^k STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

CD40; Dacetuzumab; Diffuse large B cell lymphoma; DLBCL

Indexed keywords

DACETUZUMAB; DIPHENHYDRAMINE; FC GAMMA RECEPTOR IIIA; FC RECEPTOR; PARACETAMOL; RITUXIMAB; UNCLASSIFIED DRUG; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD16 ANTIGEN; CD40 ANTIGEN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; HYPEREMIA; IMMUNOGENICITY; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OROPHARYNX PAIN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; BLURRED VISION; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFUSION; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; COUGHING; CYTOKINE RELEASE SYNDROME; DEHYDRATION; DEPRESSION; DNA POLYMORPHISM; DRUG FEVER; DRY EYE; DYSPNEA; EYE INFECTION; EYE IRRITATION; EYE PAIN; FEBRILE NEUTROPENIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; INTESTINE OBSTRUCTION; ORBIT CELLULITIS; PANCYTOPENIA; PERIPHERAL EDEMA; PNEUMONIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD40; CHILLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HEADACHE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903272348     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-44     Document Type: Article

References (24)

1. New treatment options have changed the survival of patients with follicular lymphoma. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP, J Clin Oncol 2005 23 8447 8452 10.1200/JCO.2005.03.1674 16230674
2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ, J Clin Oncol 2006 24 3121 3127 10.1200/JCO.2005.05.1003 16754935
3. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G, J Clin Oncol 2008 26 4579 4586 10.1200/JCO.2007.13.5376 18662969
4. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, Bosly A, Shpilberg O, Ketterer N, Moskowitz C, Schmitz N, J Clin Oncol 2009 27 bstract 8509
5. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Law CL, Grewal IS, Adv Exp Med Biol 2009 647 8 36 10.1007/978-0-387-89520-8-2 19760064
6. Prospects for CD40-directed experimental therapy of human cancer. Tong AW, Stone MJ, Cancer Gene Ther 2003 10 1 13 10.1038/sj.cgt.7700527 12489023
7. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS, Cancer Res 2005 65 8331 8338 10.1158/0008-5472.CAN-05-0095 16166310
8. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Hassan SB, Sorensen JF, Olsen BN, Pedersen AE, Immunopharmacol Immunotoxicol 2014 36 96 104 10.3109/08923973.2014.890626 24555495
9. Agonistic CD40 antibodies and cancer therapy. Vonderheide RH, Glennie MJ, Clin Cancer Res 2013 19 1035 1043 10.1158/1078-0432.CCR-12-2064 23460534
10. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent Non-Hodgkin's lymphoma. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG, J Clin Oncol 2009 27 4371 4377 10.1200/JCO.2008.21.3017 19636010
11. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP, J Clin Oncol 1999 17 1244 10561185
12. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC, Blood 2004 103 275 282 10.1182/blood-2003-05-1545 14504078
13. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Weng WK, Weng WK, Levy R, Leuk Lymphoma 2009 50 1494 1500 10.1080/10428190903128660 19672774
14. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N, Haematologica 2010 95 845 848 10.3324/haematol.2009.008003 20133895
15. Revised response criteria for malignant lymphoma. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, J Clin Oncol 2007 25 579 586 10.1200/JCO.2006.09.2403 17242396
16. Expression of CD40 and CD40 ligand in the human conjunctival epithelium. Bourcier T, de Saint-Jean M, Brignole F, Goguel A, Baudouin C, Invest Ophthalmol Vis Sci 2000 41 120 126 10634610
17. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, van Vloten WA, Joly P, Bagot M, Willemze R, J Clin Oncol 2001 19 3602 3610 11504742
18. WHO-EORTC classification for cutaneous lymphomas. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ, Blood 2005 105 3768 3785 10.1182/blood-2004-09-3502 15692063
19. CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TT, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagiri S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, Dornan D, Sci Transl Med 2011 3 74ra22 21411738
20. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, Zimber-Strobl U, J Exp Med 2008 205 1317 1329 10.1084/jem.20080238 18490492
21. Preclinical analysis of the combined activity of SGN-40, anti-CD40 monoclonal antibody, with rituximab in Non-Hodgkin lymphoma. Lewis TS, McCormick RS, McEarchern JA, Kissler K, Stone IJ, Gerber H-P, Drachman JG, Grewal I, Law C-L, Blood 2008 112 bstract 1583
22. The humanized anti-CD40 antibody, SGN-40, promotes apoptosis signaling and is effective in combination with standard therapies in lymphoma xenograft models. Lewis TS, Sutherland MSK, Jonas M, Cerveny CG, McCormick R, Wahl AF, Drachman JG, Grewal IS, Law C-L, Blood 2006 108 bstract 2499 10.1182/blood-2006-08-037374
23. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH, Leuk Lymphoma 2013 54 277 283 10.3109/10428194.2012. 710328 22775314
24. A phase 2B trial comparing dacetuzemab + R-ICE vs placebo + R-ICE in patients with relapsed diffuse large B-cell lymphoma. Fayad L, Ansell SM, Advani R, Coiffier B, Bartlett N, Stuart R, Forero-Torres A, Kuliczkowski K, Drachman JG, Ann Oncol 2011 22 v131 iv132